此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估种植体周围沟液中25(OH)D3与LL-37水平

2026年11月2日 更新者:Melek Beder、Recep Tayyip Erdogan University

种植体周围疾病中种植体周沟液中25(OH)D3与LL-37水平的评估

Despite technological advances that have significantly improved dental implant osseointegration and survival rates, biological complications such as peri-implantitis and peri-implant mucositis are common around the implant. The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), can be induced by the expression of leucine-lysine-37 (LL-37), a human antimicrobial peptide in the cathelicidin family. Studies have shown that 1,25(OH)2D3 and its precursor, 25(OH)D3, significantly reduce inflammation by suppressing the release of receptor activator nuclear factor kappa b ligand (RANKL), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, and IL-6, and by preventing alveolar bone loss. To date, many cytokines have been investigated in peri-implant sulcus fluid (PIOS). The lack of a direct study investigating vitamin D and LL-37 levels in PIOS constitutes the unique value of this project. This study aims to compare LL-37 and 25(OH)D3 levels in PIOS and examine their correlation with markers such as IL-6, IL-10, and MMP-8, as well as clinical parameters. Volunteers aged 18-65 who have received dental implants at the Recep Tayyip Erdoğan University Faculty of Dentistry and have been using their implant-supported prosthesis for at least one year and who have been informed about this study will be included in the study. The groups will be formed as peri-implant health, peri-implant mucositis, and peri-implantitis. The implants of the patients included in the study will be evaluated for probed pocket depth (PPD), clinical attachment level (CAL), suppuration (S), modified gingival index (mGI), plaque index (mPI), bleeding index (mBI), keratinized gingival amount, and attached gingival amount. PIOS and serum samples will be obtained from patients, and their relationship to periodontal status and each other will be statistically evaluated.

This project may help discover new biomarkers that can be used in the early diagnosis of peri-implantar diseases. This study could contribute to earlier treatment, lower patient costs, and even the development of new treatment plans for these diseases.

研究概览

地位

招聘中

条件

研究类型

观察性的

注册 (估计的)

72

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

概率样本

研究人群

The G*Power analysis performed to determine the number of samples to be included in the study determined that a total of 72 samples/implants should be included, with a minimum of 24 in each group, when the power of the test was taken as 0.85, the effect size as 0.4, and the Type-1 error (α) as 0.05.

描述

Inclusion Criteria:

  • Being between the ages of 18-65,
  • Having dental implants and using implant-supported prostheses for at least one year,
  • Not having used systemic and/or topical antibiotics/anti-inflammatory drugs or mouthwashes in the last three months,
  • Not having received periodontal/peri-implant treatment in the last six months.

Exclusion Criteria:

  • Having a systemic disease or condition that affects peri-implant status,
  • Having a metabolic bone disease,
  • Bruxism,
  • Being pregnant or lactating,
  • Having received periodontal/peri-implant treatment within the last 6 months,
  • Smoking and alcohol use,
  • Taking vitamin D supplements.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
healthy group

Criteria such as absence of clinical signs of inflammation in the tissues, absence of bleeding on probing, PPD ≤5.0 mm, and absence of bone loss greater than 2 mm after initial healing will be sought.

peri-implant mucositis

Criteria such as clinical signs of inflammation (erythema, swelling, suppuration) in the tissues, bleeding on probing, and an PPD of 5.0 mm will be sought. At the time of implant placement, the height of the surrounding soft tissue influences the initial probing depth.

periimplantitis

Bleeding, inflammation, redness, edema, suppuration, and in addition to these, bone loss >5 mm and radiographically observed in PPD are observed in the tissues.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Probing pocket depth (PPD)
大体时间:baseline

The distance from the gingival margin to the pocket base around the implants was measured in mm using a periodontal probe, at six locations for each implant. The average value will be determined for each implant circumference.

baseline
clinical attachment level (CAL)
大体时间:baseline

Similar to the PPD measurement, this will be done by determining the distance between the pocket base and the implant neck.

baseline

次要结果测量

结果测量
措施说明
大体时间
25-Hydroxy Vitamin D3 ((25(OH)D3))
大体时间:baseline

25(OH)D3 levels in PIOS samples will be analyzed by ELISA or CMIA methods.

baseline
leucine leucine-37 (LL-37)
大体时间:baseline

LL-37 levels in PIOS samples will be evaluated by ELISA method.

baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月30日

初级完成 (估计的)

2027年6月1日

研究完成 (估计的)

2027年6月1日

研究注册日期

首次提交

2025年12月1日

首先提交符合 QC 标准的

2025年12月1日

首次发布 (实际的)

2025年12月12日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2025年12月1日

更多信息

与本研究相关的术语

其他研究编号

  • Recep Tayyip Erdogan U

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.